The Elusive Promise of Savings With Biosimilars

Posted by David Weil on Sep 14, 2016 12:00:00 PM

The cost of cancer care in the United States—and its seemingly inexorable rate of growth—has been widely discussed and lamented. The cost of biologic therapies is frequently cited as a driver of this growth, and one that could be addressed with the introduction of less expensive therapeutic options. 

Read More